Walden University NURS-6521N Advanced Pharmacology
Final Exam
Latest | 100% Correct Study Guide | Download to Score A
This comprehensive final examination study guide contains 130 multiple-choice questions aligned with the
2026-2027 Walden University NURS-6521N Advanced Pharmacology curriculum for Advanced Practice Registered
Nursing. The exam is organized into eight sections covering pharmacokinetics and pharmacodynamics, autonomic
nervous system pharmacology, cardiovascular pharmacology, respiratory and endocrine pharmacology, neurological
and psychiatric pharmacology, anti-infectives and immunosuppressants, gastrointestinal and renal pharmacology,
and special populations with pharmacogenomics. Each question includes a detailed rationale explaining the correct
answer and why distractors are incorrect, emphasizing mechanism of action, pharmacokinetics, pharmacodynamics,
clinical indications, adverse effects, interactions, and evidence-based prescribing at the NP level to support mastery
of advanced pharmacology concepts.
Section 1: Pharmacokinetics and Pharmacodynamics (Absorption, Distribution,
Metabolism, Excretion, Drug Receptors, & Drug Interactions)
Q1: A patient with cirrhosis is prescribed a drug that undergoes extensive first-pass hepatic metabolism.
The NP anticipates that oral bioavailability of this drug will be:
A. Decreased, requiring higher oral doses
B. Increased, requiring lower oral doses to avoid toxicity [CORRECT]
C. Unchanged because first-pass metabolism is preserved in cirrhosis
D. Eliminated, requiring only intravenous administration
Correct Answer: B
Rationale: Cirrhosis impairs first-pass hepatic metabolism, leading to increased oral bioavailability because less
drug is metabolized before reaching systemic circulation, requiring lower oral doses to avoid toxicity. Decreased
bioavailability would occur with increased first-pass metabolism. First-pass metabolism is not preserved in cirrhosis.
IV-only is rarely required solely for first-pass issues. The NP must adjust dosing for hepatic dysfunction to prevent
drug accumulation, especially for narrow-therapeutic-index drugs such as propranolol or morphine, which have
significantly increased bioavailability in cirrhotic patients, requiring careful titration and monitoring for adverse
effects.
,Q2: A drug has a half-life of 24 hours and is dosed once daily. Approximately how long will it take to reach
steady-state plasma concentration?
A. 1 day
B. 3 days
C. 5 days (approximately 120 hours) [CORRECT]
D. 10 days
Correct Answer: C
Rationale: Approximately 5 half-lives are required to reach steady-state plasma concentration, so a drug with a
24-hour half-life takes about 120 hours (5 days) to reach steady state. One day is insufficient. Three days reaches
about 87% of steady state. Ten days is unnecessary. For drugs with long half-lives such as amiodarone (58 days),
loading doses may be used to achieve therapeutic levels more quickly while maintenance doses maintain steady state.
Understanding steady state is critical for evaluating therapeutic efficacy and avoiding premature dose adjustments
before the full effect is achieved.
Q3: A patient on warfarin is started on amiodarone. The NP should monitor closely for which interaction?
A. Amiodarone inhibits CYP2C9, increasing warfarin levels and INR, raising bleeding risk
[CORRECT]
B. Amiodarone induces warfarin metabolism, reducing INR and anticoagulant effect
C. There is no significant drug interaction between these two drugs
D. Amiodarone displaces warfarin from albumin, causing a transient increase in INR
Correct Answer: A
Rationale: Amiodarone is a potent CYP2C9 inhibitor that inhibits warfarin (S-enantiomer) metabolism, increasing
warfarin levels and INR, significantly raising bleeding risk. Warfarin dose typically needs to be reduced by 25-50%
when amiodarone is started. The interaction is not due to induction or displacement alone. The interaction is
well-documented and clinically significant. The NP should check INR within 3-5 days of starting or stopping
amiodarone, adjust the warfarin dose accordingly, educate the patient about bleeding signs, and consider alternative
antiarrhythmics if INR control becomes too difficult.
Q4: Which cytochrome P450 enzyme metabolizes most beta-blockers, many antidepressants, and codeine
to morphine?
A. CYP3A4
B. CYP2D6 [CORRECT]
C. CYP1A2
D. CYP2C9
Correct Answer: B
Rationale: CYP2D6 metabolizes many beta-blockers (metoprolol, carvedilol), antidepressants (fluoxetine, paroxetine,
venlafaxine), and converts codeine to morphine. CYP3A4 metabolizes the most drugs overall (50%) including statins,
calcium channel blockers, and macrolides. CYP1A2 metabolizes caffeine, theophylline, and clozapine. CYP2C9
metabolizes warfarin, phenytoin, and NSAIDs. CYP2D6 is significant because genetic polymorphisms create poor,
intermediate, extensive, and ultra-rapid metabolizer phenotypes that dramatically affect drug response, requiring
dose adjustments or alternative drug selection for affected patients, especially for codeine where ultra-rapid
metabolizers risk fatal morphine overdose.
,Q5: A drug follows zero-order elimination kinetics. Which statement is TRUE?
A. A constant fraction of drug is eliminated per unit time
B. A constant amount of drug is eliminated per unit time, and half-life increases with increasing
dose [CORRECT]
C. Half-life remains constant regardless of dose
D. Doubling the dose doubles the steady-state concentration
Correct Answer: B
Rationale: Zero-order kinetics means a constant amount of drug is eliminated per unit time due to saturable
metabolism, so half-life increases with increasing dose and small dose increases can cause disproportionate rises in
serum levels. A constant fraction eliminated per unit time describes first-order kinetics. Constant half-life is a feature
of first-order kinetics. Proportional dose increase is also first-order. Phenytoin, ethanol, aspirin at high doses, and
theophylline follow zero-order kinetics, requiring careful dose titration and therapeutic drug monitoring to avoid
toxicity, especially near the upper end of the therapeutic range.
Q6: Which statement BEST describes the difference between drug potency and drug efficacy?
A. Potency refers to the maximum response a drug can produce; efficacy refers to the dose needed to
produce an effect
B. Potency refers to the dose needed to produce a specific effect; efficacy refers to the maximum
response a drug can produce [CORRECT]
C. Potency and efficacy are interchangeable terms
D. Potency determines toxicity; efficacy determines side effects
Correct Answer: B
Rationale: Potency refers to the dose needed to produce a specific effect (lower dose = more potent), while efficacy
refers to the maximum response a drug can produce regardless of dose. They are not interchangeable. Potency does
not directly determine toxicity. A drug can be highly potent (low dose needed) but have low efficacy (submaximal
effect), like a partial agonist. Understanding the distinction guides drug selection: a more potent drug is not
necessarily more clinically effective, but a drug with higher efficacy may be preferred when maximum effect is needed,
such as morphine versus codeine for severe pain.
Q7: A partial agonist is administered to a patient who has been taking a full agonist at the same receptor.
What is the expected pharmacodynamic outcome?
A. The partial agonist has no effect on the full agonist
B. The partial agonist antagonizes the full agonist, reducing the overall effect [CORRECT]
C. The partial agonist enhances the full agonist's effect
D. The partial agonist irreversibly inactivates the receptor
Correct Answer: B
Rationale: A partial agonist has lower intrinsic activity than a full agonist, so when both are present at the same
receptor, the partial agonist competes for receptor occupancy and reduces the overall effect, effectively antagonizing
the full agonist. This is why buprenorphine (partial agonist at mu-opioid receptors) can precipitate withdrawal in
patients taking full opioid agonists. The partial agonist does not enhance or irreversibly inactivate the receptor. This
property is clinically useful for opioid use disorder treatment where buprenorphine provides ceiling-effect analgesia
with lower respiratory depression risk while blocking full agonist effects.
, Q8: A patient with chronic kidney disease (eGFR 25 mL/min) is prescribed a renally-cleared drug. Which
pharmacokinetic parameter is MOST affected and requires dose adjustment?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion [CORRECT]
Correct Answer: D
Rationale: Excretion is directly affected by reduced GFR, requiring dose adjustment for renally-cleared drugs such as
vancomycin, aminoglycosides, digoxin, and metformin to prevent accumulation and toxicity. Absorption is generally
unaffected by renal function. Distribution may change with fluid overload but is not the primary parameter.
Metabolism occurs primarily in the liver. The NP should calculate creatinine clearance (Cockcroft-Gault) or eGFR,
consult renal dosing references for every drug prescribed, and monitor serum drug levels and renal function to
prevent adverse drug reactions and further kidney damage, especially for drugs with narrow therapeutic indices.
Q9: Grapefruit juice inhibits which intestinal enzyme, leading to increased levels of calcium channel
blockers, statins, and some benzodiazepines?
A. CYP3A4 in the gut wall [CORRECT]
B. CYP2D6 in the liver
C. CYP1A2 in the gut
D. P-glycoprotein only
Correct Answer: A
Rationale: Grapefruit juice inhibits CYP3A4 in the gut wall (intestinal metabolism), not the liver, leading to increased
bioavailability of CYP3A4 substrates including felodipine, nifedipine, simvastatin, lovastatin, and midazolam.
CYP2D6 and CYP1A2 are not significantly affected by grapefruit. P-glycoprotein transport is also inhibited but is a
secondary mechanism. The effect can last up to 72 hours after grapefruit consumption. Patients should be counseled
to avoid grapefruit juice when taking affected drugs to prevent drug accumulation, toxicity (myopathy, hypotension,
excessive sedation), and adverse effects, or switch to alternative drugs not metabolized by CYP3A4.
Q10: Which statement describes the concept of a narrow therapeutic index (NTI) drug?
A. The dose needed for therapeutic effect is very low
B. The difference between the minimum effective dose and the minimum toxic dose is small
[CORRECT]
C. The drug has a long half-life
D. The drug is highly protein-bound
Correct Answer: B
Rationale: A narrow therapeutic index (NTI) drug has a small difference between the minimum effective dose and the
minimum toxic dose, requiring careful dosing and therapeutic drug monitoring. Examples include warfarin, digoxin,
lithium, phenytoin, theophylline, aminoglycosides, and vancomycin. A low therapeutic dose is not the definition. Long
half-life and high protein binding are separate concepts. NTI drugs require serum level monitoring, individualized
dosing, careful attention to drug interactions, and patient education about adherence and signs of toxicity, because
small changes in dose or absorption can have significant clinical consequences.
Final Exam
Latest | 100% Correct Study Guide | Download to Score A
This comprehensive final examination study guide contains 130 multiple-choice questions aligned with the
2026-2027 Walden University NURS-6521N Advanced Pharmacology curriculum for Advanced Practice Registered
Nursing. The exam is organized into eight sections covering pharmacokinetics and pharmacodynamics, autonomic
nervous system pharmacology, cardiovascular pharmacology, respiratory and endocrine pharmacology, neurological
and psychiatric pharmacology, anti-infectives and immunosuppressants, gastrointestinal and renal pharmacology,
and special populations with pharmacogenomics. Each question includes a detailed rationale explaining the correct
answer and why distractors are incorrect, emphasizing mechanism of action, pharmacokinetics, pharmacodynamics,
clinical indications, adverse effects, interactions, and evidence-based prescribing at the NP level to support mastery
of advanced pharmacology concepts.
Section 1: Pharmacokinetics and Pharmacodynamics (Absorption, Distribution,
Metabolism, Excretion, Drug Receptors, & Drug Interactions)
Q1: A patient with cirrhosis is prescribed a drug that undergoes extensive first-pass hepatic metabolism.
The NP anticipates that oral bioavailability of this drug will be:
A. Decreased, requiring higher oral doses
B. Increased, requiring lower oral doses to avoid toxicity [CORRECT]
C. Unchanged because first-pass metabolism is preserved in cirrhosis
D. Eliminated, requiring only intravenous administration
Correct Answer: B
Rationale: Cirrhosis impairs first-pass hepatic metabolism, leading to increased oral bioavailability because less
drug is metabolized before reaching systemic circulation, requiring lower oral doses to avoid toxicity. Decreased
bioavailability would occur with increased first-pass metabolism. First-pass metabolism is not preserved in cirrhosis.
IV-only is rarely required solely for first-pass issues. The NP must adjust dosing for hepatic dysfunction to prevent
drug accumulation, especially for narrow-therapeutic-index drugs such as propranolol or morphine, which have
significantly increased bioavailability in cirrhotic patients, requiring careful titration and monitoring for adverse
effects.
,Q2: A drug has a half-life of 24 hours and is dosed once daily. Approximately how long will it take to reach
steady-state plasma concentration?
A. 1 day
B. 3 days
C. 5 days (approximately 120 hours) [CORRECT]
D. 10 days
Correct Answer: C
Rationale: Approximately 5 half-lives are required to reach steady-state plasma concentration, so a drug with a
24-hour half-life takes about 120 hours (5 days) to reach steady state. One day is insufficient. Three days reaches
about 87% of steady state. Ten days is unnecessary. For drugs with long half-lives such as amiodarone (58 days),
loading doses may be used to achieve therapeutic levels more quickly while maintenance doses maintain steady state.
Understanding steady state is critical for evaluating therapeutic efficacy and avoiding premature dose adjustments
before the full effect is achieved.
Q3: A patient on warfarin is started on amiodarone. The NP should monitor closely for which interaction?
A. Amiodarone inhibits CYP2C9, increasing warfarin levels and INR, raising bleeding risk
[CORRECT]
B. Amiodarone induces warfarin metabolism, reducing INR and anticoagulant effect
C. There is no significant drug interaction between these two drugs
D. Amiodarone displaces warfarin from albumin, causing a transient increase in INR
Correct Answer: A
Rationale: Amiodarone is a potent CYP2C9 inhibitor that inhibits warfarin (S-enantiomer) metabolism, increasing
warfarin levels and INR, significantly raising bleeding risk. Warfarin dose typically needs to be reduced by 25-50%
when amiodarone is started. The interaction is not due to induction or displacement alone. The interaction is
well-documented and clinically significant. The NP should check INR within 3-5 days of starting or stopping
amiodarone, adjust the warfarin dose accordingly, educate the patient about bleeding signs, and consider alternative
antiarrhythmics if INR control becomes too difficult.
Q4: Which cytochrome P450 enzyme metabolizes most beta-blockers, many antidepressants, and codeine
to morphine?
A. CYP3A4
B. CYP2D6 [CORRECT]
C. CYP1A2
D. CYP2C9
Correct Answer: B
Rationale: CYP2D6 metabolizes many beta-blockers (metoprolol, carvedilol), antidepressants (fluoxetine, paroxetine,
venlafaxine), and converts codeine to morphine. CYP3A4 metabolizes the most drugs overall (50%) including statins,
calcium channel blockers, and macrolides. CYP1A2 metabolizes caffeine, theophylline, and clozapine. CYP2C9
metabolizes warfarin, phenytoin, and NSAIDs. CYP2D6 is significant because genetic polymorphisms create poor,
intermediate, extensive, and ultra-rapid metabolizer phenotypes that dramatically affect drug response, requiring
dose adjustments or alternative drug selection for affected patients, especially for codeine where ultra-rapid
metabolizers risk fatal morphine overdose.
,Q5: A drug follows zero-order elimination kinetics. Which statement is TRUE?
A. A constant fraction of drug is eliminated per unit time
B. A constant amount of drug is eliminated per unit time, and half-life increases with increasing
dose [CORRECT]
C. Half-life remains constant regardless of dose
D. Doubling the dose doubles the steady-state concentration
Correct Answer: B
Rationale: Zero-order kinetics means a constant amount of drug is eliminated per unit time due to saturable
metabolism, so half-life increases with increasing dose and small dose increases can cause disproportionate rises in
serum levels. A constant fraction eliminated per unit time describes first-order kinetics. Constant half-life is a feature
of first-order kinetics. Proportional dose increase is also first-order. Phenytoin, ethanol, aspirin at high doses, and
theophylline follow zero-order kinetics, requiring careful dose titration and therapeutic drug monitoring to avoid
toxicity, especially near the upper end of the therapeutic range.
Q6: Which statement BEST describes the difference between drug potency and drug efficacy?
A. Potency refers to the maximum response a drug can produce; efficacy refers to the dose needed to
produce an effect
B. Potency refers to the dose needed to produce a specific effect; efficacy refers to the maximum
response a drug can produce [CORRECT]
C. Potency and efficacy are interchangeable terms
D. Potency determines toxicity; efficacy determines side effects
Correct Answer: B
Rationale: Potency refers to the dose needed to produce a specific effect (lower dose = more potent), while efficacy
refers to the maximum response a drug can produce regardless of dose. They are not interchangeable. Potency does
not directly determine toxicity. A drug can be highly potent (low dose needed) but have low efficacy (submaximal
effect), like a partial agonist. Understanding the distinction guides drug selection: a more potent drug is not
necessarily more clinically effective, but a drug with higher efficacy may be preferred when maximum effect is needed,
such as morphine versus codeine for severe pain.
Q7: A partial agonist is administered to a patient who has been taking a full agonist at the same receptor.
What is the expected pharmacodynamic outcome?
A. The partial agonist has no effect on the full agonist
B. The partial agonist antagonizes the full agonist, reducing the overall effect [CORRECT]
C. The partial agonist enhances the full agonist's effect
D. The partial agonist irreversibly inactivates the receptor
Correct Answer: B
Rationale: A partial agonist has lower intrinsic activity than a full agonist, so when both are present at the same
receptor, the partial agonist competes for receptor occupancy and reduces the overall effect, effectively antagonizing
the full agonist. This is why buprenorphine (partial agonist at mu-opioid receptors) can precipitate withdrawal in
patients taking full opioid agonists. The partial agonist does not enhance or irreversibly inactivate the receptor. This
property is clinically useful for opioid use disorder treatment where buprenorphine provides ceiling-effect analgesia
with lower respiratory depression risk while blocking full agonist effects.
, Q8: A patient with chronic kidney disease (eGFR 25 mL/min) is prescribed a renally-cleared drug. Which
pharmacokinetic parameter is MOST affected and requires dose adjustment?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion [CORRECT]
Correct Answer: D
Rationale: Excretion is directly affected by reduced GFR, requiring dose adjustment for renally-cleared drugs such as
vancomycin, aminoglycosides, digoxin, and metformin to prevent accumulation and toxicity. Absorption is generally
unaffected by renal function. Distribution may change with fluid overload but is not the primary parameter.
Metabolism occurs primarily in the liver. The NP should calculate creatinine clearance (Cockcroft-Gault) or eGFR,
consult renal dosing references for every drug prescribed, and monitor serum drug levels and renal function to
prevent adverse drug reactions and further kidney damage, especially for drugs with narrow therapeutic indices.
Q9: Grapefruit juice inhibits which intestinal enzyme, leading to increased levels of calcium channel
blockers, statins, and some benzodiazepines?
A. CYP3A4 in the gut wall [CORRECT]
B. CYP2D6 in the liver
C. CYP1A2 in the gut
D. P-glycoprotein only
Correct Answer: A
Rationale: Grapefruit juice inhibits CYP3A4 in the gut wall (intestinal metabolism), not the liver, leading to increased
bioavailability of CYP3A4 substrates including felodipine, nifedipine, simvastatin, lovastatin, and midazolam.
CYP2D6 and CYP1A2 are not significantly affected by grapefruit. P-glycoprotein transport is also inhibited but is a
secondary mechanism. The effect can last up to 72 hours after grapefruit consumption. Patients should be counseled
to avoid grapefruit juice when taking affected drugs to prevent drug accumulation, toxicity (myopathy, hypotension,
excessive sedation), and adverse effects, or switch to alternative drugs not metabolized by CYP3A4.
Q10: Which statement describes the concept of a narrow therapeutic index (NTI) drug?
A. The dose needed for therapeutic effect is very low
B. The difference between the minimum effective dose and the minimum toxic dose is small
[CORRECT]
C. The drug has a long half-life
D. The drug is highly protein-bound
Correct Answer: B
Rationale: A narrow therapeutic index (NTI) drug has a small difference between the minimum effective dose and the
minimum toxic dose, requiring careful dosing and therapeutic drug monitoring. Examples include warfarin, digoxin,
lithium, phenytoin, theophylline, aminoglycosides, and vancomycin. A low therapeutic dose is not the definition. Long
half-life and high protein binding are separate concepts. NTI drugs require serum level monitoring, individualized
dosing, careful attention to drug interactions, and patient education about adherence and signs of toxicity, because
small changes in dose or absorption can have significant clinical consequences.
